The natural history of tricuspid regurgitation is associated to hospitalization for cardiac failure and mortality. This is why the AHA/ACC guidelines recommend surgery when the tricuspid fails during left valve surgical repair, because its slow progression is associated with high mortality (35%). Many of these patients are high risk and percutaneous intervention has surged as<a href="https://solaci.org/en/2023/05/12/latest-developments-in-tricuspid-regurgitation/" title="Read more" >...</a>
SOLACI@EuroPCR 2023 Joint Session at EuroPCR 2023
Once more, the Latin American Society of Interventional Cardiology will be at EuroPCR 2023, one of the most important events of the specialty in the world. In the segment “How to Treat (coronary interventions, valve interventions, bifurcation lesions, STEMI, TAVR) – Focus on International Collaboration” we will deliver a joint session on research registries in<a href="https://solaci.org/en/2023/05/08/solacieuropcr-2023-joint-session-at-europcr-2023/" title="Read more" >...</a>
Low Gradient Aortic Stenosis: Is Invasive Assessment Viable?
There is an important group of patients presenting low flow, low-gradient severe aortic stenosis (defined as mean gradient <40 mmHg). This is why we do dobutamine stress echocardiogram (DSE), to confirm whether we are dealing with truly severe aortic stenosis. However, it might not be well tolerated and a CT angiography will be done to<a href="https://solaci.org/en/2023/05/08/low-gradient-aortic-stenosis-is-invasive-assessment-viable/" title="Read more" >...</a>
BASILICA: a Complex Strategy, Yet Safe
Coronary artery obstruction (CAO) after TAVR is rare, but it entails extremely high mortality (50% or more), especially after valve-in-valve (V-in-V) or when the coronary ostia are is too close to the valve annulus. This is why the BASILICA technique was developed (Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction).<a href="https://solaci.org/en/2023/05/04/basilica-a-complex-strategy-yet-safe/" title="Read more" >...</a>
Evolute Low Risk at 3 Years: Promising Outcomes
Transcatheter aortic valve replacement has shown important benefits but one of its biggest challenges is showing its safety and efficacy at followup in low risk patients. At present we have 2-year data from the Evolute Low Risk, but the we lack information at longer followup. The study looked at 3-year followup of the Evolute Low<a href="https://solaci.org/en/2023/05/03/evolute-low-risk-at-3-years-promising-outcomes/" title="Read more" >...</a>
PICCOLETO-II: Drug-Coated Balloons in Small Vessels
Use of drug-coated balloons vs. drug-eluting stents in small caliber vessels. The constant advancements in coronary device technology have significantly reduced complication rates (such as that of restenosis). However, there are gaps where a high number of undesirable events prevail, such as small vessel disease (SVD), for which, in previous studies up, the rate of<a href="https://solaci.org/en/2023/04/28/piccoleto-ii-drug-coated-balloons-in-small-vessels/" title="Read more" >...</a>
Clinical Impact of Coronary Artery Disease on Results After TAVR
Coronary artery disease (CAD) coexists with aortic stenosis in about half the patients who suffer the latter. These patients receiving antiplatelet therapy are at a higher risk of periprocedural bleeding—one of the most frequent complications in patients who undergo transcatheter aortic valve replacement (TAVR). One way of limiting the risk for bleeding is choosing the<a href="https://solaci.org/en/2023/04/17/clinical-impact-of-coronary-artery-disease-on-results-after-tavr/" title="Read more" >...</a>
The most read scientific articles in interventional cardiology in March on our website
Below, we share March’s most read scientific abstracts in interventional cardiology at solaci.org. ACC 2023 | YELLOW III Study. Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease Dr. Kini presented the results of the YELLOW III Study where she analyzed the effect of evolocumab on coronary plaque in patients with stable<a href="https://solaci.org/en/2023/04/13/the-most-read-scientific-articles-in-interventional-cardiology-in-march-on-our-website/" title="Read more" >...</a>
Percutaneous Access Closure in TAVR: Are Devices Similar?
One of the challenges that transcatheter aortic valve replacement (TAVR) continues to face is percutaneous access closure with percutaneous closure systems (PCS). However, several systems have been developed, either by plug—such as the MANTA system—or by suture (SU)—such as the ProStar and ProGlide systems. Both of these have been tested in different analyses, but to<a href="https://solaci.org/en/2023/04/12/percutaneous-access-closure-in-tavr-are-devices-similar/" title="Read more" >...</a>
Prosthesis Mismatch in TAVR: It’s Real Impact
Prosthesis-patient mismatch (PPM) was initially proposed by Rahimtoola and reintroduced by Pirabot. PPM is the indexed effective orifice area in relation to body surface area, cutoff value being 0.85 cm2/m2, and <0.70 cm2/m2for obese patients. PPM is considered moderate if indexed effective orifice area is 0.65-0.85 cm2/m2 and severe when <0.65 cm2/m2 Research studies on surgical prosthesis have<a href="https://solaci.org/en/2023/04/05/prosthesis-mismatch-in-tavr-its-real-impact/" title="Read more" >...</a>